Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01039883 · ClinicalTrials.gov registry record · Phase 1
A Study to Compare the Blood Levels of Albaconazole in Healthy Subjects Who Have Received a Single Dose of 400 mg Albaconazole as a Tablet Versus Albaconazole as a Capsule
A Phase 1 study, sponsored by Stiefel, a GSK Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
NCT01039883 is a Phase 1 study that has completed, run by Stiefel, a GSK Company. The registered enrollment target is 40 participants.
The verdict
NCT01039883, a Phase 1 study, has completed, sponsored by Stiefel, a GSK Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether albaconazole tablets and albaconazole capsules (single 400mg dose) act in the body in the same way over a period of time.
Interventions
- DRUG Albaconazole tablet 400mg
- DRUG Albaconazole 100mg capsules, then albaconazole 400mg tablet
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2009-11-23 |
| Est. Completion | 2010-01-20 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01039883
The ClinicalTrials.gov registry entry for NCT01039883 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stiefel, a GSK Company, which has 37 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Albaconazole tablet 400mg is the first listed.
NCT01039883 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01039883 about?
NCT01039883 is a clinical study titled "A Study to Compare the Blood Levels of Albaconazole in Healthy Subjects Who Have Received a Single Dose of 400 mg Albaconazole as a Tablet Versus Albaconazole as a Capsule". The purpose of this study is to determine whether albaconazole tablets and albaconazole capsules (single 400mg dose) act in the body in the same way over a period of time.
What is the current status of trial NCT01039883?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2009-11-23. Estimated completion is 2010-01-20.
What interventions are being tested in trial NCT01039883?
The interventions under investigation include: Albaconazole tablet 400mg (DRUG), Albaconazole 100mg capsules, then albaconazole 400mg tablet (DRUG).
Who is sponsoring clinical trial NCT01039883?
This trial is sponsored by Stiefel, a GSK Company, which has 37 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.